Afterward, new ROS1–TKIs got into clinical trial, leading to the FDA and Ministry of Health, Labor and Welfare of Japan approvals of entrectinib for the treatment of ROS1‐aberrant NSCLC. Here, ROS1 is linked to non-small cell lung carcinoma.